Berkeley, CA, United States of America

Tilmann M Brotz

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Tilmann M Brotz

Introduction

Tilmann M Brotz is a notable inventor based in Berkeley, California. He has made significant contributions to the field of biotechnology, particularly in the development of long-acting parathyroid hormone peptides. His work has the potential to greatly impact the treatment of various medical conditions related to calcium and phosphate metabolism.

Latest Patents

Brotz holds a patent for a long-acting parathyroid hormone peptide (PTH). This invention provides a peptide that is retained in a subject's blood serum for periods that greatly exceed the natural hormone. The long-acting PTH is conjugated to a non-hormonal vitamin D at the carbon 3 position via a scaffold that facilitates purification, detection, solubility, and efficacy at the PTH receptor. The PTH may be conjugated to the non-hormonal vitamin D through a 36 mer poly(ethylene glycol) moiety, known as PTH-PEG36-VitD. This innovative approach results in a vastly improved serum half-life and bioavailability compared to non-conjugated PTH peptides. Additionally, PTH-PEG36-VitD significantly increases serum calcium, reduces urinary calcium, and lowers serum phosphate levels.

Career Highlights

Brotz is currently associated with Extend Biosciences, Inc., where he continues to advance his research and development efforts. His work in the field of peptide therapeutics has garnered attention for its potential applications in treating metabolic disorders.

Collaborations

Some of his notable coworkers include Tarik Soliman and Daniel B Hall, who contribute to the collaborative efforts in research and development at Extend Biosciences, Inc.

Conclusion

Tilmann M Brotz's innovative work in the development of long-acting parathyroid hormone peptides represents a significant advancement in biotechnology. His contributions have the potential to improve treatment options for patients with metabolic disorders related to calcium and phosphate.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…